Business Description
Insmed Inc
NAICS : 325412
SIC : 2834
ISIN : US4576693075
Share Class Description:
LTS:0JAV: Ordinary SharesTotal Employee Number:
1,664Description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.11 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 0.82 | |||||
Debt-to-EBITDA | -0.54 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.79 | |||||
Beneish M-Score | -1.01 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.2 | |||||
3-Year EBITDA Growth Rate | -17.6 | |||||
3-Year EPS without NRI Growth Rate | -10.8 | |||||
3-Year FCF Growth Rate | -13.4 | |||||
3-Year Book Growth Rate | 74.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 82.54 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 8.39 | |||||
9-Day RSI | 22.59 | |||||
14-Day RSI | 32.75 | |||||
3-1 Month Momentum % | -19.49 | |||||
6-1 Month Momentum % | -29.56 | |||||
12-1 Month Momentum % | -0.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.47 | |||||
Quick Ratio | 4.1 | |||||
Cash Ratio | 3.39 | |||||
Days Inventory | 290.99 | |||||
Days Sales Outstanding | 43.42 | |||||
Days Payable | 178.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.5 | |||||
Shareholder Yield % | 2.57 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.81 | |||||
Operating Margin % | -117.77 | |||||
Net Margin % | -144.44 | |||||
EBITDA Margin % | -132.18 | |||||
FCF Margin % | -112.45 | |||||
OCF Margin % | -109.29 | |||||
ROE % | -158.33 | |||||
ROA % | -53.89 | |||||
ROIC % | -180.21 | |||||
3-Year ROIIC % | -321.38 | |||||
ROC (Joel Greenblatt) % | -836.25 | |||||
ROCE % | -59.96 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 25.29 | |||||
PB Ratio | 30.25 | |||||
Price-to-Tangible-Book | 45.65 | |||||
EV-to-EBIT | -18.85 | |||||
EV-to-Forward-EBIT | -31.44 | |||||
EV-to-EBITDA | -19.16 | |||||
EV-to-Forward-EBITDA | -39.15 | |||||
EV-to-Revenue | 25.33 | |||||
EV-to-Forward-Revenue | 12.18 | |||||
EV-to-FCF | -22.46 | |||||
Price-to-GF-Value | 0.53 | |||||
| Price-to-Net-Current-Asset-Value | 89.23 | |||||
Earnings Yield (Greenblatt) % | -5.3 | |||||
FCF Yield % | -4.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Insmed Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 819.564 | ||
| EPS (TTM) ($) | -5.75 | ||
| Beta | 0.7079 | ||
| 3-Year Sharpe Ratio | 0.85 | ||
| 3-Year Sortino Ratio | 2.99 | ||
| Volatility % | 56.56 | ||
| 14-Day RSI | 32.75 | ||
| 14-Day ATR ($) | 4.464864 | ||
| 20-Day SMA ($) | 107.945587 | ||
| 12-1 Month Momentum % | -0.3 | ||
| 52-Week Range ($) | 91.59 - 214 | ||
| Shares Outstanding (Mil) | 216.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Insmed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Insmed Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:00 | In 86 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 85 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | In 1 day | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 97.77 (-4.05%) | ||
| Goldman Sachs Annual Global Healthcare Conference | 2026-06-09 10:00 | 92.66 (-3.63%) | ||
| Guidance call for 2026 | 2026-05-20 10:30 | 107.35 (-1.51%) | ||
| General meeting for 2026 | 2026-05-13 09:00 | 115.55 (+9.47%) | ||
| Guidance call for 2026 | 2026-05-12 13:40 | 106.00 (+2.55%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 138.82 (-1.39%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 138.82 (-1.39%) |
Show
Entries
Insmed Inc Frequently Asked Questions
What is Insmed Inc(LTS:0JAV)'s stock price today?
The current price of LTS:0JAV is $99.05. The 52 week high of LTS:0JAV is $214.00 and 52 week low is $91.59.
When is next earnings date of Insmed Inc(LTS:0JAV)?
The next earnings date of Insmed Inc(LTS:0JAV) is 2026-08-06.
Does Insmed Inc(LTS:0JAV) pay dividends? If so, how much?
Insmed Inc(LTS:0JAV) does not pay dividend.
Press Release
Articles on Insmed Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers